The Manila Times

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line ...
The Manila Times

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Surviv…

After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in ...